多发性硬化症患者停用那他珠单抗后白细胞粘附分子动力学
Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis.
作者信息
Cobo-Calvo Álvaro, Figueras Agnes, Bau Laura, Matas Elisabet, Mañé Martínez María Alba, León Isabel, Majòs Carles, Romero-Pinel Lucia, Martínez-Yélamos Sergio
机构信息
Multiple Sclerosis Unit, Bellvitge University Hospital - IDIBELL, L'Hospitalet de LLobregat, Barcelona, Spain; Department of Neurology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Laboratori de Recerca Translacional ICO-IDIBELL, Laboratorio de investigación ICO-IDIBELL, L'Hospitalet de LLobregat, Barcelona, Spain.
出版信息
Clin Immunol. 2016 Oct;171:18-24. doi: 10.1016/j.clim.2016.08.003. Epub 2016 Aug 3.
Cell-adhesion molecules (CAMs) dynamics in Multiple Sclerosis (MS) patients have been widely studied after Natalizumab (NTZ) introduction. However, their temporal dynamics after NTZ withdrawal (NTZ-W) has not been described. We prospectively evaluate changes in the expression levels of CAMs (CD49d, CD29, L-Selectin and CD11a) involved in T cell migration of 22 MS patients after NTZ-W. CD49d, CD29 and CD11a expression experienced a continuous increase expression two months after NTZ-W and Cd49d expression at month six after NTZ-W correlated to NTZ treatment duration, both in CD45CD4 and CD45CD8. CD49d expression up to month three after NTZ-W was related to MS activity in CD45CD8 at the end of the study. Results from this study suggest that patients with a longer NTZ treatment are more susceptible to present a "molecular rebound" after NTZ-W. CD49d determination may be a useful tool to closely monitor MS activity in patients who interrupt NTZ.
在引入那他珠单抗（NTZ）后，多发性硬化症（MS）患者体内细胞黏附分子（CAMs）的动态变化已得到广泛研究。然而，NTZ撤药（NTZ-W）后其时间动态变化尚未见报道。我们前瞻性评估了22例MS患者在NTZ-W后参与T细胞迁移的CAMs（CD49d、CD29、L-选择素和CD11a）表达水平的变化。NTZ-W后两个月，CD49d、CD29和CD11a的表达持续增加，且NTZ-W后六个月时，CD49d在CD45CD4和CD45CD8中的表达与NTZ治疗持续时间相关。在研究结束时，NTZ-W后三个月内CD49d的表达与CD45CD8中的MS活动相关。本研究结果表明，接受NTZ治疗时间较长的患者在NTZ-W后更易出现“分子反弹”。测定CD49d可能是密切监测中断NTZ治疗患者MS活动的有用工具。
Zotero 插件